Marco Island, Fla., Feb. 24, 2025 – MGI Tech Co., Ltd. (“MGI”), a company committed to building core tools and technologies that drive innovation in life science, today unveiled its latest high- performance sequencing solutions at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting through its US subsidiary Complete Genomics . The newly introduced DNBSEQ-T1+* and DNBSEQ-E25 Flash* are designed to deliver speed, flexibility, and efficiency, empowering researchers with faster, high-quality genomic data.

DNBSEQ-T1+: Mid-Throughput Sequencing with Industry-Leading Speed

The DNBSEQ-T1+ is a next-generation mid-throughput sequencer that completes a paired end 150

sequencing workflow in just 24 hours with Q40 accuracy. With three flow cell formats, two to four addressable lanes on each flow cell, along with dual independent flow cell operation, the DNBSEQ-T1+ provides increased data output with reduced turnaround time which enables increased lab efficiency and flexibility. With a throughput range of 25–1,200 Gb, a maximum capacity exceeding 1 Tb daily, DNBSEQ-T1+ allows laboratories to reduce the time to result that is important in a range of laboratory settings. The DNBSEQ-T1+ integrated auto-DNB making and loading capabilities enables a straightforward, user-friendly workflow. This design offers the flexibility to process multiple samples independently without requiring barcodes, leverage independent flow cell lanes and start the sequencing workflow in less than ten minutes with minimal hands-on time.

“The DNBSEQ-T1+ brings a new level of efficiency, output and cost to mid-throughput sequencing, offering output and pricing typical of previous higher output systems while providing laboratories the speed and flexibility needed for a wide range of genomic applications – such as Whole Genome Sequencing, Single Cell, Spatial, Oncology, Rare Disease and Metagenomics – all within a streamlined, user-friendly workflow,” said Rob Tarbox, VP of Product and Marketing at Complete Genomics.

The newly launched DNBSEQ-T1+ mid-throughput sequencer joins the established DNBSEQ-T7 high-throughput, DNBSEQ-G99 and DNBSEQ-E25 low-throughput platforms in achieving sub-24-hour sequencing run times for PE150 read lengths. The 24-hour sequencing framework across the sequencing portfolio enables laboratories to maximize their output while retaining flexibility and control across various laboratory settings.

In addition, the DNBSEQ-T1+ has optimized the internal design of the instrument, significantly reducing the number of reagents required for sequencing. Additionally, coupled with high-density flow cells, DNBSEQ-T1+ has reduced the cost per Gb. This allows laboratories, even small or mid-sized, to achieve the cost per Gb of a production-scale sequencer when using this benchtop sequencer. DNBSEQ-T1+ is currently available for pre-order globally.

DNBSEQ-E25 Flash: AI-Enhanced Sequencing in Under Two Hours 

The DNBSEQ-E25 Flash is an upgraded instrument from its existing portable DNBSEQ-E25 sequencer. It redefines portable sequencing with AI-driven enhancements. Building on self-luminescence technology and a CMOS-based flow cell, this next-generation sequencer leverages AI-optimized protein engineering for enhanced signal intensity and precision.

An AI-powered base calling system deployed on an edge device powered by the NVIDIA Jetson platform accelerates sequencing to new speeds. A single-substrate injection eliminates the need for traditional dual-luciferase systems, reducing cycle times to just one minute and enabling SE50 sequencing in under two hours.

* For Research Use Only. Not for use in diagnostic procedures.

About MGI

MGI Tech Co., Ltd.  (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. 

MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/ , Linkedin, X, and Youtube.